Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery

Frontiers in Immunology

Volumn 2, Issue DEC, 2011, Pages

  Bouvier, Isabelle ^a,b   Jusforgues Saklani, Hélène ^a,b   Lim, Annick ^a   Lemaître, Fabrice ^a,c   Lemercier, Brigitte ^a   Auriau, Charlotte ^a,b   Nicola, Marie Anne ^a   Leroy, Sandrine ^a   Law, Helen K ^a   Bandeira, Antonio ^a   Moon, James J ^d,e   Bousso, Philippe ^a,c   Albert, Matthew L ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adjuvant delivery; Cross priming; Dentritic cells; Polyfunctional T cells

Indexed keywords

EID: 84874462885     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2011.00071     Document Type: Article

References (55)

1. Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., Holman, R. M., Shapiro, R. L., Berman, R. S., Berner, N., Shao, Y., Manches, O., Pan, L., Venhaus, R. R., Hoffman, E. W., Jungbluth, A., Gnjatic,S.,Old,L.,Pavlick,A. C.,and Bhardwaj, N. (2008). Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181, 776-784.
2. Albert, M. L. (2004). Death-defying immunity: do apoptotic cells influ-ence antigen processing and pre-sentation? Nat. Rev. Immunol. 4, 223-231.
3. Albert, M. L., Jegathesan, M., and Dar-Nell, R. B. (2001). Dendritic cell mat-uration is required for the cross-tolerization of CD8+ T cells. Nat. Immunol. 2, 1010-1017.
4. Albert, M. L., Sauter, B., and Bhardwaj, N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89.
5. Almeida, J. R., Price, D. A., Papagno, L., Arkoub, Z. A., Sauce, D., Bornstein, E.,Asher, T. E., Samri,A., Schnuriger, A., Theodorou, I., Costagliola, D., Rouzioux, C., Agut, H., Marcelin, A. G., Douek, D.,Autran, B., and Appay, V. (2007). Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunc-tionality, and clonal turnover. J. Exp. Med. 204, 2473-2485.
6. Altman, J. D., Moss, P. A., Goulder, P. J., Barouch, D. H., Mcheyzer-Williams, M. G., Bell, J. I., Mcmichael, A. J., and Davis, M. M. (1996). Pheno-typic analysis of antigen-specific T lymphocytes. Science 274, 94-96.
7. Amigorena, S. (2000). Cancer immunotherapy using dendritic cell-derived exosomes. Medicina (B Aires) 60(Suppl. 2), 51-54.
8. Badovinac,V. P., Haring, J. S., and Harty, J. T. (2007). Initial T cell recep-tor transgenic cell precursor fre-quency dictates critical aspects of the CD8(+) T cell response to infection. Immunity 26, 827-841.
9. Bennett, S. R., Carbone, F. R., Kara-Malis, F., Flavell, R. A., Miller, J. F., and Heath, W. R. (1998). Help for cytotoxic-T-cell responses is medi-ated by CD40 signalling. Nature 393, 478-480.
10. Bennett, S. R., Carbone, F. R., Kara-Malis, F., Miller, J. F., and Heath, W. R. (1997). Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 186, 65-70.
11. Blachere, N. E., Morris, H. K., Braun, D., Saklani, H., Di Santo, J. P., Dar-Nell, R. B., and Albert, M. L. (2006). IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation. J. Immunol. 176, 7288-7300.
12. Bousso, P., Casrouge, A., Altman, J. D., Haury, M., Kanellopoulos, J., Abas-Tado, J. P., and Kourilsky, P. (1998). Individual variations in the murine T cell response to a specific pep-tide reflect variability in naive reper-toires. Immunity 9, 169-178.
13. Buckwalter, M. R., and Srivastava, P. K. (2008). "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. Semin. Immunol. 20, 296-300.
14. Carralot,J. P.,Probst,J.,Hoerr,I.,Scheel, B., Teufel, R., Jung, G., Rammensee, H. G., and Pascolo, S. (2004). Polar-ization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell. Mol. Life Sci. 61, 2418-2424.
15. Catron, D. M., Rusch, L. K., Hataye, J., Itano, A. A., and Jenkins, M. K. (2006). CD4+ T cells that enter the draining lymph nodes after anti-gen injection participate in the pri-mary response and become central-memory cells. J. Exp. Med. 203, 1045-1054.
16. Celli, S., Garcia, Z., and Bousso, P. (2005). CD4 T cells integrate sig-nals delivered during successive DC encounters in vivo. J. Exp. Med. 202, 1271-1278.
17. Darrah, P. A., Patel, D. T., De Luca, P. M., Lindsay, R. W., Davey, D. F., Flynn, B. J., Hoff, S. T., Andersen, P., Reed, S. G., Morris, S. L., Roederer, M., and Seder, R. A. (2007). Multi-functional TH1 cells define a corre-late of vaccine-mediated protection against leishmania major. Nat. Med. 13, 843-850.
18. den Haan, J. M., Lehar, S. M., and Bevan, M. J. (2000). CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685-1696.
19. Diken, M., Kreiter, S., Selmi, A., Brit-Ten, C. M., Huber, C., Tureci, O., and Sahin, U. (2011). Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 18, 702-708.
20. Dillon, S. R., Jameson, S. C., and Fink, P. J. (1994). V beta 5+ Tcellreceptors skew toward OVA+ H-2Kb recogni-tion. J. Immunol. 152, 1790-1801.
21. Edelson, B. T., Kc, W., Juang, R., Kohyama, M., Benoit, L. A., Klekotka, P. A., Moon, C., Albring, J. C., Ise, W., Michael, D. G., Bhattacharya, D., Stappenbeck, T. S., Holtzman, M. J., Sung, S. S., Murphy, T. L., Hildner, K., and Murphy, K. M. (2010). Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J. Exp. Med. 207, 823-836.
22. Flynn, B. J., Kastenmuller, K., Wille-Reece, U., Tomaras, G. D., Alam, M., Lindsay, R. W., Salazar, A. M., Perdiguero, B., Gomez, C. E., Wag-Ner, R., Esteban, M., Park, C. G., Trumpfheller, C., Keler, T., Panta-Leo, G., Steinman, R. M., and Seder, R. (2011). Immunization with HIV Gag targeted to dendritic cells fol-lowed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 108, 7131-7136.
23. Fontana, R., Bregni, M., Cipponi, A., Raccosta, L., Rainelli, C., Maggioni, D., Lunghi, F., Ciceri, F., Mukenge, S., Doglioni, C., Colau, D., Coulie, P. G., Bordignon, C., Traversari, C., and Russo, V. (2009). Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce anti-tumor immune responses in cancer patients. Blood 113, 1651-1660.
24. Heemels, M. T., and Ploegh, H. (1995). Generation, translocation, and pre-sentation of MHC class I-restricted peptides. Annu. Rev. Biochem. 64, 463-491.
25. Jusforgues-Saklani, H., Uhl, M., Blachere, N., Lemaitre, F., Lantz, O., Bousso, P., Braun, D., Moon, J. J., and Albert, M. L. (2008). Antigen persistence is required for dendritic cell licensing and CD8+ Tcell cross-priming. J. Immunol. 181, 3067-3076.
26. Kearney, E. R., Pape, K. A., Loh, D. Y., and Jenkins, M. K. (1994). Visualization of peptide-specific T cell immunity and peripheral toler-ance induction in vivo. Immunity 1, 327-339.
27. Krebs, P., Barnes, M. J., Lampe, K., Whitley, K., Bahjat, K. S., Beutler, B., Janssen, E., and Hoebe, K. (2009). NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood 113, 6593-6602.
28. Kurts, C., Heath, W. R., Carbone, F. R., Allison, J., Miller, J. F., and Kosaka, H. (1996). Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184, 923-930.
29. Lanzavecchia, A. (1998). Immunology. Licence to kill. Nature 393, 413-414.
30. Longhi, M. P., Trumpfheller, C., Idoy-Aga, J., Caskey, M., Matos, I., Kluger, C., Salazar, A. M., Colonna, M., and Steinman, R. M. (2009). Den-dritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206, 1589-1602.
31. Marzo, A. L., Klonowski, K. D., Le Bon, A., Borrow, P., Tough, D. F., and Lefrancois, L. (2005). Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat. Immunol. 6, 793-799.
32. Mellman, I., and Steinman, R. M. (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258.
33. Mitchell, M. S., Abrams, J., Thompson, J. A., Kashani-Sabet, M., Deconti, R. C., Hwu, W. J., Atkins, M. B., Whit-Man, E., Ernstoff, M. S., Haluska, F. G., Jakowatz, J. G., DAS Gupta, T. K., Richards, J. M., Samlowski, W. E., Costanzi, J. J., Aronson, F. R., Deis-Seroth,A. B.,Dudek,A. Z.,and Jones, V. E. (2007). Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for resected stage III cuta-neous melanoma. J. Clin. Oncol. 25, 2078-2085.
34. Moon, J. J., Chu, H. H., Pepper, M., Mcsorley, S. J., Jameson, S. C., Kedl, R. M., and Jenkins, M. K. (2007). Naive CD4(+) T cell fre-quency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27 203-213.
35. Nicodemus,C. F.,and Berek,J. S. (2010). TLR3 agonists as immunothera-peutic agents. Immunotherapy 2, 137-140.
36. Nierkens, S., Den Brok, M. H., Sut-Muller,R. P., Grauer,O. M., Bennink, E., Morgan, M. E., Figdor, C. G., Ruers, T. J., and Adema, G. J. (2008). In vivo colocalization of antigen and CpG (corrected) within dendritic cells is associated with the efficacy of cancer immunotherapy. Cancer Res. 68, 5390-5396.
37. Obar, J. J., Khanna, K. M., and Lefrancois, L. (2008). Endogenous naive CD8+ T cell precursor fre-quency regulates primary and mem-ory responses to infection. Immunity 28, 859-869.
38. Okada, H., Kalinski, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T. E., Mintz, A. H., Engh, J. A., Bartlett, D. L., Brown, C. K., Zeh, H., Holtz-Man, M. P., Reinhart, T. A., White-Side, T. L., Butterfield, L. H., Hamil-Ton, R. L., Potter, D. M., Pollack, I. F., Salazar, A. M., and Lieberman, F. S. (2011). Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clin-ical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and car-boxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29, 330-336.
39. Palucka, A. K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J. P., Johnston, D. A., Fay, J., and Banchereau, J. (2006). Dendritic cells loaded with killed allogeneic melanoma cells can induce objec-tive clinical responses and MART-1 specific CD8+ T-cell immunity. J. Immunother. 29, 545-557.
40. Pannetier, C., Cochet, M., Darche, S., Casrouge, A., Zoller, M., and Kouril-Sky, P. (1993). The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc. Natl. Acad. Sci. U.S.A. 90, 4319-4323.
41. Precopio, M. L., Betts, M. R., Parrino, J., Price, D. A., Gostick, E., Ambrozak, D. R., Asher, T. E., Douek, D. C., Harari, A., Pantaleo, G., Bailer, R., Graham, B. S., Roederer, M., and Koup, R. A. (2007). Immunization with vaccinia virus induces poly-functional and phenotypically dis-tinctive CD8(+) T cell responses. J. Exp. Med. 204, 1405-1416.
42. Prlic, M., Hernandez-Hoyos, G., and Bevan, M. J. (2006). Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. J. Exp. Med. 203, 2135-2143.
43. Rehli, M. (2002). Of mice and men: species variations of Toll-like recep-tor expression. Trends Immunol. 23, 375-378.
44. Ridge, J. P., Di Rosa, F., and Matzinger, P. (1998). A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478.
45. Rosenfeld, M. R., Chamberlain, M. C., Grossman, S. A., Peereboom, D. M., Lesser,G. J.,Batchelor,T. T.,Desideri, S., Salazar, A. M., and Ye, X. (2010). A multi-institution phase II study of poly-ICLC,and radiotherapy with concurrent, and adjuvant temozolo-mide in adults with newly diag-nosed glioblastoma. Neuro Oncol. 12, 1071-1077.
46. Russo, V., Cipponi, A., Raccosta, L., Rainelli, C., Fontana, R., Mag-Gioni, D., Lunghi, F., Mukenge, S., Ciceri, F., Bregni, M., Bordignon, C., and Traversari, C. (2007). Lympho-cytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J. Clin. Invest. 117, 3087-3096.
47. Schoenberger, S. P., Toes, R. E., Van Der Voort, E. I., Offringa, R., and Melief, C. J. (1998). T-cell help for cyto-toxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483.
48. Seder, R. A., Darrah, P. A., and Roederer, M. (2008). T-cell quality in memory and protection: implications for vac-cine design. Nat. Rev. Immunol. 8, 247-258.
49. Tewari, K., Flynn, B. J., Boscardin, S. B., Kastenmueller, K., Salazar, A. M., Anderson, C. A., Soundarapandian, V., Ahumada, A., Keler, T., Hoffman, S. L., Nussenzweig, M. C., Stein-man, R. M., and Seder, R. A. (2010). Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plas-modium falciparum circumsporo-zoite protein (CSP) and alphaDEC-CSP in non human primates.Vaccine 28, 7256-7266.
50. Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., Pavlick, A., Escalon, J. B., Cruz, C. M., Angiulli, A., Angiulli, F., Mears, G., Vogel, S. M., Pan, L., Jungbluth, A. A., Hoffmann, E. W., Venhaus, R., Ritter, G., Old, L. J., and Ayyoub, M. (2007). Vacci-nation with NY-ESO-1 protein and CpG in Montanide induces inte-grated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl. Acad. Sci. U.S.A. 104, 8947-8952.
51. van Heijst, J. W., Gerlach, C., Swart, E., Sie, D., Nunes-Alves, C., Kerkhoven, R. M., Arens, R., Correia-Neves, M., Schepers, K., and Schumacher, T. N. (2009). Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science 325, 1265-1269.
52. Weide, B., Carralot, J. P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H. G., Garbe, C., and Pascolo, S. (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31, 180-188.
53. Wilson, N. S., Behrens, G. M., Lundie, R. J.,Smith,C. M.,Waithman,J.,Young, L., Forehan, S. P., Mount,A., Steptoe, R. J., Shortman, K. D., De Koning-Ward,T. F.,Belz,G. T.,Carbone,F. R., Crabb, B. S., Heath, W. R., and Vil-ladangos, J. A. (2006). Systemic acti-vation of dendritic cells by Toll-like receptor ligands or malaria infec-tion impairs cross-presentation and antiviral immunity. Nat. Immunol. 7, 165-172.
54. Wolfers, J., Lozier, A., Raposo, G., Reg-Nault, A., Thery, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., Angevin, E., Amigorena, S., and Zitvogel, L. (2001). Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7, 297-303.
55. Zehn, D., Lee, S. Y., and Bevan, M. J. (2009). Complete but curtailed T-cell response to very low-affinity antigen. Nature 458, 211-214